TL;DR / Evidence Grade: AOD 9604 carries an Evidence Grade C+ for mild, targeted fat loss without systemic metabolic disruption. Cagrilintide boasts an Evidence Grade A for profound, systemic weight reduction via satiety signaling. As of 2026, AOD 9604 faces strict FDA Category 2 compounding bans, whereas Cagrilintide is advancing rapidly through late-stage clinical trials.
The weight loss peptide landscape is splitting into two distinct camps. On one side, legacy lipolytic agents aim to burn fat without altering systemic metabolism. On the other, next-generation satiety hormones are driving surgical-level weight reduction.
Comparing AOD 9604 vs Cagrilintide illustrates this divide perfectly.
AOD 9604 is a modified fragment of human growth hormone designed strictly to mobilize stored fat. Cagrilintide is a long-acting amylin analog that fundamentally rewires hunger signals and delays gastric emptying.
Understanding their differences is critical for anyone evaluating metabolic peptides.
Mechanisms of Action: How They Drive Weight Loss
A peptide's mechanism dictates its ceiling for results. These two compounds operate on completely different biological pathways to influence body composition.
AOD 9604: Targeted Lipolysis
AOD 9604 is a synthetic analog of the C-terminal region of human growth hormone, specifically amino acids 177-191.
It mimics the fat-burning effects of native growth hormone without triggering the associated metabolic downsides. Specifically, it stimulates lipolysis (the breakdown of fat) and inhibits lipogenesis (the formation of new fat cells).
Crucially, AOD 9604 does not bind to growth hormone receptors. This means it lacks the typical GH side effects, such as insulin resistance, elevated blood sugar, or increased IGF-1 levels.
Cagrilintide: Amylin-Mediated Satiety
Cagrilintide operates entirely within the gut-brain axis. It is a long-acting synthetic analog of amylin, a hormone naturally co-secreted with insulin by the pancreas after a meal.
Amylin receptors in the brain regulate hunger, meal termination, and reward-based eating behaviors. By agonizing these receptors, Cagrilintide induces profound, sustained satiety.
It also slows gastric emptying, keeping food in the stomach longer to prolong fullness. When paired with GLP-1 agonists, this dual-action mechanism creates a powerful synergistic effect on weight loss.
Efficacy and Clinical Evidence for Weight Management
Clinical data separates theoretical fat burners from proven metabolic interventions. The evidence gap between these two peptides is substantial.
AOD 9604 (Evidence Grade: C+)
AOD 9604 was initially developed by Metabolic Pharmaceuticals as an anti-obesity drug under the research name INV102.
Early human trials showed initial promise. A 12-week randomized controlled trial involving 300 obese patients demonstrated minor weight loss and improved lipid profiles compared to a placebo.
Here is the catch: subsequent Phase 2b trials failed to meet primary endpoints for significant, sustained weight loss.
The data suggests AOD 9604 may support modest body composition changes and localized fat reduction, but it is not a standalone solution for clinical obesity. Most current research has pivoted toward its potential joint-healing properties rather than AOD 9604 weight loss applications.
Cagrilintide (Evidence Grade: A)
Cagrilintide's clinical trajectory is vastly different, backed by robust data from Novo Nordisk's REDEFINE trial program.
In Phase 2 trials (NCT04982575), patients taking Cagrilintide alone achieved an average weight loss of 10.8% over 26 weeks.
The real breakthrough is combination therapy. When co-administered with semaglutide (a combination known as CagriSema), patients achieved up to 15.6% body weight reduction in a 32-week Phase 2 trial.
This clinical trial data positions Cagrilintide as one of the most potent metabolic peptides currently in development, directly rivaling dual-agonists like tirzepatide.
Commonly Reported Dosing Protocols
The following protocols reflect clinical trial data and commonly reported clinical practices. They are not medical recommendations.
AOD 9604 Dosing
Because of its short half-life, AOD 9604 requires frequent administration to maintain stable blood levels.
- Dose Range: 250mcg to 500mcg daily.
- Route of Administration: Subcutaneous injection.
- Frequency: Once daily, typically administered in the morning on an empty stomach or prior to cardiovascular exercise.
- Cycle Length: 8 to 12 weeks, followed by a washout period.
Cagrilintide Dosing
Cagrilintide is engineered with a prolonged half-life, allowing for convenient weekly dosing similar to modern GLP-1 medications.
- Dose Range: Titrated gradually up to 2.4mg per week (based on Phase 2/3 clinical trial protocols).
- Route of Administration: Subcutaneous injection.
- Frequency: Once weekly.
- Cycle Length: Continuous use under medical supervision for chronic weight management.
Side Effects & Safety Profiles
Every peptide carries a distinct risk profile. Because these two compounds act on different physiological systems, their side effects rarely overlap.
AOD 9604 Risks
AOD 9604 is generally well-tolerated, largely because it does not impact systemic hormone levels or insulin sensitivity.
- Injection site reactions: Mild redness, swelling, or itching at the subcutaneous injection site.
- Systemic effects: Occasional headaches, mild flushing, or temporary indigestion.
- Contraindications: While it does not elevate IGF-1 like standard growth hormone, patients with active malignancies are generally advised to avoid GH fragments.
Cagrilintide Risks
Because Cagrilintide fundamentally alters digestion and neurological hunger signals, its side effect profile is much heavier and requires careful management.
- Gastrointestinal issues: Nausea, vomiting, and constipation are highly common, particularly during the initial dose titration phase.
- Fatigue: Often reported secondary to drastically reduced caloric intake.
- Hypoglycemia risk: While low on its own, the risk of low blood sugar increases if combined with insulin or sulfonylureas.
- Contraindications: Individuals with a history of gastroparesis, severe eating disorders, or severe gastrointestinal disease should avoid amylin analogs.
FDA & Legal Status (USA 2026)
The regulatory landscape for peptides has shifted dramatically over the last few years, directly impacting the availability of both compounds.
AOD 9604: Category 2 Restrictions
AOD 9604 is not an FDA-approved drug for any indication.
Historically, it was widely available through telehealth clinics and compounding pharmacies. However, the FDA has officially classified AOD 9604 as a Category 2 substance under its bulk compounding regulations.
This means the FDA has determined it lacks sufficient clinical evidence or safety data to be compounded for human use. As of 2026, legitimate US compounding pharmacies cannot legally dispense AOD 9604.
For more context on how these restrictions impact patient access, review our guide on FDA Category 1 & 2 peptides.
Cagrilintide: Investigational New Drug
Cagrilintide is currently an investigational new drug navigating late-stage FDA trials.
It is not yet approved for standalone prescription use or pharmacy compounding. However, the CagriSema combination is on a fast track for FDA approval, targeting patients who have plateaued on standard GLP-1 therapies.
Until formal approval is granted, Cagrilintide remains accessible only through sanctioned clinical trials or strictly regulated research channels.
Which Peptide is Right for You? (Comparative Summary)
Choosing between these metabolic peptides depends entirely on the scale of weight loss required, individual tolerance for gastrointestinal side effects, and regulatory access.
Here is how they stack up side-by-side.
| Feature | AOD 9604 | Cagrilintide |
|---|---|---|
| Primary Mechanism | Lipolysis (Fat breakdown) | Amylin receptor agonist (Satiety) |
| Clinical Target | Mild body composition changes | Severe clinical obesity |
| Typical Weight Loss | < 5% | 10% - 15%+ |
| Major Side Effects | Injection site redness, headache | Nausea, vomiting, delayed gastric emptying |
| FDA Status | Category 2 (Compounding banned) | Investigational (Phase 3 trials) |
| Evidence Grade | C+ | A |
If you are exploring other metabolic or weight loss options, consider reviewing our comparison of AOD 9604 vs. Tirzepatide or AOD 9604 vs. Retatrutide.
Bottom Line
The data paints a clear picture of two very different compounds operating on opposite ends of the weight management spectrum.
AOD 9604 offers a mild, targeted approach to fat loss with minimal side effects. However, its lack of clinical efficacy in large human trials and restrictive FDA Category 2 status make it largely obsolete for serious weight management protocols.
Cagrilintide represents the frontier of anti-obesity medication. Its ability to command satiety, delay gastric emptying, and synergize with GLP-1 agonists makes it a dominant force in clinical trials, despite a heavier gastrointestinal side effect profile.
This content is for educational purposes only and is not medical advice. Consult a healthcare professional before starting any peptide protocol.